The Genome Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.
PLoS Pathog. 2013;9(8):e1003505. doi: 10.1371/journal.ppat.1003505. Epub 2013 Aug 1.
Parasitic roundworm infections plague more than 2 billion people (1/3 of humanity) and cause drastic losses in crops and livestock. New anthelmintic drugs are urgently needed as new drug resistance and environmental concerns arise. A "chokepoint reaction" is defined as a reaction that either consumes a unique substrate or produces a unique product. A chokepoint analysis provides a systematic method of identifying novel potential drug targets. Chokepoint enzymes were identified in the genomes of 10 nematode species, and the intersection and union of all chokepoint enzymes were found. By studying and experimentally testing available compounds known to target proteins orthologous to nematode chokepoint proteins in public databases, this study uncovers features of chokepoints that make them successful drug targets. Chemogenomic screening was performed on drug-like compounds from public drug databases to find existing compounds that target homologs of nematode chokepoints. The compounds were prioritized based on chemical properties frequently found in successful drugs and were experimentally tested using Caenorhabditis elegans. Several drugs that are already known anthelmintic drugs and novel candidate targets were identified. Seven of the compounds were tested in Caenorhabditis elegans and three yielded a detrimental phenotype. One of these three drug-like compounds, Perhexiline, also yielded a deleterious effect in Haemonchus contortus and Onchocerca lienalis, two nematodes with divergent forms of parasitism. Perhexiline, known to affect the fatty acid oxidation pathway in mammals, caused a reduction in oxygen consumption rates in C. elegans and genome-wide gene expression profiles provided an additional confirmation of its mode of action. Computational modeling of Perhexiline and its target provided structural insights regarding its binding mode and specificity. Our lists of prioritized drug targets and drug-like compounds have potential to expedite the discovery of new anthelmintic drugs with broad-spectrum efficacy.
寄生虫性蠕虫感染困扰着超过 20 亿人(占全球人口的 1/3),并导致农作物和牲畜的巨大损失。随着新的耐药性和环境问题的出现,迫切需要新的驱虫药物。“关键反应”定义为消耗独特底物或产生独特产物的反应。关键分析提供了一种系统的方法来识别新的潜在药物靶点。在 10 种线虫物种的基因组中鉴定出了关键酶,并找到了所有关键酶的交集和并集。通过研究和实验测试已知靶向与线虫关键蛋白同源的蛋白的现有化合物,本研究揭示了使关键酶成为成功药物靶点的特征。在公共数据库中针对与线虫关键蛋白同源的蛋白的已知化合物进行了化学基因组筛选,以寻找针对线虫关键蛋白同源物的现有化合物。根据在成功药物中经常发现的化学性质对化合物进行优先级排序,并使用秀丽隐杆线虫进行实验测试。确定了几种已知的驱虫药物和新的候选靶点。对 7 种化合物在秀丽隐杆线虫中进行了测试,其中 3 种产生了有害表型。这 3 种类似药物的化合物之一,己酮可可碱,也对寄生形式不同的两种线虫,扭形线虫和细颈线虫产生了有害影响。己酮可可碱已知会影响哺乳动物的脂肪酸氧化途径,导致秀丽隐杆线虫的耗氧量降低,全基因组基因表达谱进一步证实了其作用模式。己酮可可碱及其靶标的计算建模提供了关于其结合模式和特异性的结构见解。我们优先考虑的药物靶点和类似药物的化合物列表有可能加速广谱疗效的新驱虫药物的发现。